

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity**

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1693989> since 2019-02-23T19:05:15Z

*Published version:*

DOI:10.1016/j.antiviral.2019.02.006

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1  
2  
3 **The Isoquinoline Alkaloid Berberine Inhibits Human Cytomegalovirus Replication by**  
4  
5 **Interfering with the Viral Immediate Early-2 (IE2) Protein Transactivating Activity**  
6  
7  
8

9  
10 Anna Luginini<sup>1,3</sup>, Beatrice Mercorelli<sup>2,3</sup>, Lorenzo Messa<sup>2</sup>, Giorgio Palù<sup>2</sup>, Giorgio Gribaudo<sup>1,4\*</sup>,  
11  
12 Arianna Loregian<sup>2,4\*</sup>  
13  
14  
15  
16  
17

18 <sup>1</sup>Department of Life Sciences and Systems Biology, University of Turin, 10123 Turin, Italy.  
19

20 <sup>2</sup>Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.  
21

22 <sup>3</sup>Co-first author.  
23

24 <sup>4</sup>Co-senior author.  
25

26 \*Correspondence: [giorgio.gribaudo@unito.it](mailto:giorgio.gribaudo@unito.it); [arianna.loregian@unipd.it](mailto:arianna.loregian@unipd.it)  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 **Abbreviations:** BBR, berberine; IE2, Immediate-Early 2; IE3, Immediate-Early 3; GCV,  
48  
49 ganciclovir; CDV, cidofovir; FOS, foscarnet; NTZ, nitazoxanide.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

60  
61  
62 **Abstract**  
63

64 The identification and validation of new small molecules able to inhibit the replication of  
65 human cytomegalovirus (HCMV) remains a priority to develop alternatives to the currently used  
66 DNA polymerase inhibitors, which are often burdened by long-term toxicity and emergence of  
67 cross-resistance. To contribute to this advancement, here we report on the characterization of the  
68 mechanism of action of a bioactive plant-derived alkaloid, berberine (BBR), selected in a previous  
69 drug repurposing screen expressly devised to identify early inhibitors of HCMV replication. Low  
70 micromolar concentrations of BBR were confirmed to suppress the replication of different HCMV  
71 strains, including clinical isolates and strains resistant to approved DNA polymerase inhibitors.  
72 Analysis of the HCMV replication cycle in infected cells treated with BBR then revealed that the  
73 bioactive compound compromised the progression of virus cycle at a stage prior to viral DNA  
74 replication and Early (E) genes expression, but after Immediate-Early (IE) proteins expression.  
75 Mechanistic studies in fact highlighted that BBR interferes with the transactivating functions of the  
76 viral IE2 protein, thus impairing efficient E gene expression and the progression of HCMV  
77 replication cycle. Finally, the mechanism of the antiviral activity of BBR appears to be conserved  
78 among different CMVs, since BBR suppressed murine CMV (MCMV) replication and inhibited the  
79 transactivation of the prototypic MCMV *E1* gene by the IE3 protein, the murine homolog of IE2.  
80 Together, these observations warrant for further experimentation to obtain proof of concept that  
81 BBR could represent an attractive candidate for alternative anti-HCMV therapeutic strategies.  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107

108 **Keywords:** Berberine chloride; Human Cytomegalovirus; Murine Cytomegalovirus; IE2; IE3;  
109 Promoter transactivation.  
110  
111  
112  
113  
114  
115  
116  
117  
118

## 1. Introduction

Human cytomegalovirus (HCMV) represents one of the most important opportunistic human pathogens. It belongs to the *Beta-herpesvirinae* subfamily and rarely causes symptomatic clinical manifestations in immunocompetent individuals (Griffiths et al., 2015; Lukanini et al., 2016; Britt & Prichard, 2018). However, HCMV induces severe morbidity and mortality in the immunocompromised population following reactivation or primary infection, leading to gastrointestinal diseases, pneumonia, retinitis, and other organs' infections (Griffiths et al., 2015; Lukanini et al., 2016). Moreover, HCMV is also the viral leading cause of congenital defects in newborn children, causing deafness and other neurological disorders in approximately 0.1% cases of congenital infections (Britt, 2018). Understanding the molecular mechanisms of HCMV replication and identifying essential viral and host factors involved in productive infection is mandatory for the development of new effective antiviral agents and therapeutic strategies that could fill the gap left by the currently approved anti-HCMV therapies. In fact, the drugs available for the treatment of HCMV infections suffer from several drawbacks, including long-term toxicity and poor bioavailability (Meesing and Razonable, 2018). In addition, since the anti-HCMV drugs all share a common target (i.e., the viral DNA polymerase), the possibility may occur that drug-resistant viruses selected during long-term therapy are also cross-resistant to all the available drugs, leaving the patient bereft of therapeutic options (Haidar and Singh, 2017; Razonable, 2018). A step forward was the very recent approval of letermovir, a viral terminase inhibitor, albeit only as a prophylactic agent for preventing HCMV disease in patients undergoing hematopoietic stem cells transplantation (Bray et al., 2018; Marty et al., 2017). For all these reasons, there is an evident medical need for the development of new anti-HCMV drugs with a favorable pharmacological profile and directed against different viral targets.

The multifunctional and essential viral Immediate-Early 2 (IE2) protein is thought one of the most promising new targets for anti-HCMV drug discovery, and over time targeting IE2 expression

178  
179  
180 or activity has been proven to represent an effective antiviral strategy ((Scholz et al., 2001;  
181  
182 Mercorelli et al., 2014a). Indeed, ISIS 2922 (fomivirsen), an antisense phosphorothioate  
183  
184 oligonucleotide complementary to the mRNA encoding IE2 and thus able to prevent IE2 protein  
185  
186 expression, is a drug approved for treatment of HCMV diseases, although infrequently used  
187  
188 compared to ganciclovir (GCV) (Britt & Prichard, 2018). More recently, several small molecules,  
189  
190 including already approved drugs, have been reported to interfere with the expression or activity of  
191  
192 IE2 (Mercorelli et al., 2014b; Gardner et al., 2015; Mercorelli et al., 2016; Beelontally et al., 2017;  
193  
194 Mercorelli et al., 2018a). In detail, we focused on the gene transactivating activity of IE2 (Stinski &  
195  
196 Petrik, 2008) as a HCMV-specific target for a drug-repurposing cell-based screening of a library of  
197  
198 both approved drugs and natural bioactive compounds (Mercorelli et al., 2016). Among the 38  
199  
200 identified hits, the anti-parasitic drug nitazoxanide (NTZ) was observed to inhibit HCMV  
201  
202 replication, as well as viral Early (E) and Late (L) gene expression and DNA synthesis. Mechanistic  
203  
204 studies then revealed that NTZ hindered the IE2-dependent transactivation of essential viral E genes  
205  
206 (Mercorelli et al., 2016). NTZ represents therefore the prototype of a novel class of anti-HCMV  
207  
208 agents that can act by interfering with the transactivating activity of IE2. The natural compound  
209  
210 berberine hydrochloride (BBR) was another of the molecules selected by the screening that showed  
211  
212 a potent inhibitory activity on HCMV replication at low-micromolar concentrations (Mercorelli et  
213  
214 al., 2016).

215  
216  
217  
218 BBR is an isoquinoline alkaloid that can be isolated from different plants belonging to the  
219  
220 *Berberis* genus and is a traditional component of Chinese and Ayurvedic medicine used since  
221  
222 millenniums for its antimicrobial and antiparasitic effects (Imenshahidi and Hosseinzadeh, 2016;  
223  
224 Kumar et al., 2015). Currently, BBR is under preclinical and clinical investigation for its broad-  
225  
226 spectrum pharmacological properties, including anti-cancer, anti-diabetes, and anti-hypertensive  
227  
228 activities (Imenshahidi and Hosseinzadeh, 2016; Kumar et al., 2015). An inhibitory activity of BBR  
229  
230 have been already reported against different viruses, such as herpesviruses (herpes simplex virus  
231  
232 and HCMV) (Song et al., 2014; Hayashi et al., 2007), influenza virus (Cecil et al., 2011),  
233  
234  
235  
236

237  
238  
239 respiratory syncytial virus (RSV) (Shin et al., 2015), alphavirus (Varghese et al., 2016a; Varghese  
240 et al., 2016b), enterovirus (Wang et al., 2017), and flavivirus (Robinson et al., 2018). Moreover,  
241  
242 BBR is used as a common dietary supplement all over the world and thus its repurposing potential  
243  
244 is high.  
245  
246

247  
248 However, in the case of HCMV, the mechanism of the antiviral activity of BBR has not  
249  
250 been investigated. Here, we report the characterization of the mechanism of action of BBR against  
251  
252 both HCMV and the murine cytomegalovirus (MCMV) and provide strong evidence that BBR  
253  
254 targets the activity of the HCMV transcription factor IE2, as well as of its murine homolog IE3.  
255  
256

## 257 258 **2. Materials & Methods**

### 259 260 *2.1 Compounds*

261  
262 Berberine chloride (BBR), nitazoxanide (NTZ), foscarnet (FOS), and ganciclovir (GCV)  
263  
264 were purchased from Sigma-Aldrich. Cidofovir (CDV) was from Gilead Sciences. Fomivirsen (ISIS  
265  
266 2922) was synthesized by Metabion International AG. The anti-HCMV 6-aminoquinolone  
267  
268 compound WC5 was previously described (Mercorelli et al., 2009).  
269  
270

### 271 272 *2.2 Cells and viruses*

273  
274 Human Foreskin Fibroblasts (HFF), low-passage number human embryonic lung fibroblasts  
275  
276 (HELFL), U373-MG, and NIH 3T3 cells were cultured in Dulbecco modified Eagle's medium  
277  
278 (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Euroclone), 2 mM  
279  
280 glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 µg/ml streptomycin sulfate (P/S,  
281  
282 both from Euroclone) at 37°C in a humidified atmosphere supplemented with 5% CO<sub>2</sub>. Quiescent  
283  
284 HELFs were obtained by culturing the subconfluent cultures for 48 h in DMEM supplemented with  
285  
286 0.5% serum (low-serum medium).  
287  
288

289  
290 HCMV laboratory strain AD169 was purchased from American Type Culture Collection  
291  
292 (ATCC; VR-538). HCMV TB40-UL32-EGFP (kindly provided by C. Sinzger, University of Ulm,  
293  
294  
295

296  
297  
298 Germany) was previously described (Sampaio et al., 2005). HCMV VR1814 (kindly provided by G.  
299  
300 Gerna, IRCCS Policlinico San Matteo, Pavia, Italy) was recovered from a cervical swab from a  
301  
302 pregnant woman (Revello et al., 2001). HCMV 388438U, a clinical isolate of HCMV, was collected  
303  
304 from a urine sample at the Microbiology and Virology Unit of Padua University Hospital (Italy) and  
305  
306 was at passage 4 after primary isolation. HCMV strains resistant to antiviral drugs were obtained  
307  
308 from the NIH AIDS Research and Reference Reagent Program (Rockville, MD) and were  
309  
310 previously described (Mercorelli et al., 2009). Murine cytomegalovirus (MCMV) strain Smith was  
311  
312 purchased from the ATCC (ATCC VR-194). Recombinant adenoviral vectors expressing HCMV  
313  
314 IE2 or *E. coli*  $\beta$ -galactosidase (LacZ) were previously described (Mercorelli et al., 2014).  
315  
316  
317  
318  
319

### 320 *2.3 Plaque reduction assays*

321  
322 For plaque reduction assays (PRA) with HCMV and MCMV, HFF and NIH 3T3 cells,  
323  
324 respectively, were seeded in 24-well plates. The next day, cell monolayers were infected at 37°C  
325  
326 with 100 Plaque Forming Units (PFU) per well of the different viral strains. At 2 h post-infection  
327  
328 (p.i.), viral inocula were removed, cells were washed, and media containing increasing  
329  
330 concentrations of each compound, 5% FBS, and 0.6% methylcellulose were added. All compound  
331  
332 concentrations were tested at least in duplicate. After 10 days for HCMV and 6 days for MCMV,  
333  
334 cell monolayers were fixed, stained with crystal violet, and viral plaques were microscopically  
335  
336 counted.  
337  
338  
339  
340

### 341 *2.4 Cytotoxicity assays*

342  
343 The cytotoxicity of BBR and reference compounds were determined by the 3-(4,5-  
344  
345 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) method, as  
346  
347 described previously (Loregian and Coen, 2006).  
348  
349  
350

### 351 *2.5 Quantitative Real-Time PCR*

355  
356  
357 To analyze the effects of BBR on HCMV DNA synthesis, HFFs were seeded at a density of  
358  
359  $1.5 \times 10^5$  per well in 24-well plates. The next day, cell monolayers were infected with HCMV  
360  
361 AD169 at a multiplicity of infection (MOI) of 0.1 PFU/cell and, following virus adsorption (2 h at  
362  
363 37°C), were incubated with 50  $\mu$ M BBR or 25  $\mu$ M GCV as a control. At different times p.i., cells  
364  
365 were collected and total DNA was extracted. The levels of viral DNA were then determined by  
366  
367 quantitative Real-time PCR (qPCR) and normalized to the cellular  *$\beta$ -globin* gene copies as  
368  
369 previously described (Loregian et al., 2010). The oligonucleotide sequences used for the qPCR  
370  
371 experiments were previously reported (Mercorelli et al., 2016).  
372  
373  
374  
375

## 376 *2.6 Immunoblotting*

377

378 Sub-confluent HFF cells cultured in 6-well plates were infected with HCMV AD169 at an  
379  
380 MOI of 0.5 PFU/cell. Following virus adsorption, cells were treated with 50  $\mu$ M BBR, 30  $\mu$ M NTZ,  
381  
382 or with DMSO (0.1% v/v) as a control. Whole-cell protein extracts were prepared at different times  
383  
384 p.i. as previously described (Cavaletto et al., 2015), fractionated through 8% SDS-PAGE, and then  
385  
386 transferred to PVDF membranes (BioRad). After blocking with 5% nonfat dry milk in TBS-Tween  
387  
388 0.05%, membranes were incubated overnight at 4°C with the following mAbs: anti-IEA (IE1 and  
389  
390 IE2) (1:2000, clone CH160, Virusys), anti-UL44 (1:2000, clone CH16, Virusys), anti-UL99  
391  
392 (1:2000, clone H19, Virusys), and anti-tubulin (1:2000, clone TUB 2.1, Sigma) as a control for  
393  
394 protein loading. Immunocomplexes were then detected with a goat anti-mouse Ig Ab conjugated to  
395  
396 horseradish peroxidase (Life Technologies) and visualized by enhanced chemiluminescence  
397  
398 (Western Blotting Luminol Reagent, Santa Cruz).  
399  
400  
401  
402  
403

## 404 *2.7 Plasmids*

405

406 The pUL54-luciferase indicator plasmids pUL54-0.4, bearing the entire HCMV *UL54*  
407  
408 promoter, and pUL54-0.15, containing *UL54* promoter sequence from -150 to +15 relative to the  
409  
410 transcription start site, were previously described (Gariano et al., 2012). pRL-TK and pSV-Rluc  
411  
412  
413



414  
415  
416 vectors expressing *Renilla* luciferase were purchased from Promega. The indicator plasmids pE(-  
417 207)Luc and pME(-207)Luc containing the firefly luciferase reporter gene under control of wt and  
418 207)Luc and pME(-207)Luc containing the firefly luciferase reporter gene under control of wt and  
419 mutated cellular cyclin E promoter, respectively, were kindly provided by E.A. Thompson (Mayo  
420 Clinic Florida, FL) and were previously described (Bresnahan et al., 1998). Generation of the  
421 pGL3-MIEP-crs wt plasmid expressing firefly luciferase under the control of HCMV Major  
422 Immediate Early promoter was previously described (Mercorelli et al., 2014). The pGL4.10-luc2-  
423 LTR construct expressing the luciferase indicator gene under the control of HIV-1 LTR was  
424 previously described (Perrone et al., 2013). pRPneo/SL3/Tat expressing HIV-1 Tat protein was  
425 previously described (Gibellini et al., 1995). The firefly luciferase indicator construct phTS-  
426 243/+30 contains a portion of the promoter of the human thymidylate synthase gene (TS) (-243 and  
427 +30 relative to the transcription start codon) cloned into pGL3-basic vector (Promega) (Gribaudo et  
428 al., 2002). The pSGIE72 and pSGIE86 constructs, expressing the HCMV IE1-72 kDa or IE2-86  
429 kDa proteins respectively, were generated as described previously (Klucher et al., 1993). The empty  
430 pSG5 expression vector was purchased from Agilent Technologies. The pGL3-E1 vector, harboring  
431 the MCMV early gene *E1* promoter responsive to IE3 protein (the MCMV homolog of HCMV  
432 IE2), was generated as previously reported (Mercorelli et al., 2014). The pIE3 plasmid for the  
433 expression of IE3 was described previously (Messerle et al., 1992). pBSK plasmid was purchased  
434 from Agilent Technologies.

## 454 2.9 Cell transfection and adenoviral transduction

455  
456  
457 All transient transfection experiments in HELF cells were performed using Lipofectamine  
458 3000 (Life Technologies). For transfection/transduction experiments, HELF grown on 24-well  
459 plates were transfected with the luciferase reporter plasmid driven by either the UL54-0.4 or UL54-  
460 0.15 gene promoter, and the pRL-TK plasmid expressing *Renilla* luciferase to normalize variations  
461 in transfection efficiency (Mercorelli et al., 2016). At 24 h post-transfection, cells were transduced  
462 with AdvIE2, or AdvLacZ as a control, at an MOI of 20 PFU/cell for 2 h at 37°C, and then treated  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472

473  
474  
475 with 50  $\mu$ M BBR, 30  $\mu$ M NTZ, 5  $\mu$ M ISIS 2922, or 0.1% DMSO (v/v). At 48 h post-transduction,  
476  
477 cell extracts were prepared and firefly and *Renilla* luciferase activities were measured.  
478

479  
480 To evaluate the effect of BBR on the TS gene promoter activity, HELF cells were co-  
481  
482 transfected with phTS-243/+30, pSGIE72, or the empty pSG5 vector, along with pRL-TK plasmid.  
483  
484 At 18 h post-transfection, cells were washed with warm medium and incubated in low-serum  
485  
486 medium (0.2% FBS) containing 50  $\mu$ M BBR, 30  $\mu$ M NTZ, or 0.1% DMSO (v/v) for 48 h before  
487  
488 measuring firefly and *Renilla* luciferases activities (Gribaudo et al., 2002; Mercorelli et al., 2018).  
489  
490 Transient transfections in U373-MG cells were performed using calcium phosphate precipitation  
491  
492 method (CellPect Transfection Kit, GE Healthcare). Briefly, U373-MG were seeded in 24-well  
493  
494 plates and the next day were transiently co-transfected with 0.5  $\mu$ g of plasmids containing different  
495  
496 promoters (*cyclin E* both wt and mutated, HCMV MIEP, and HIV-1 LTR) and, where indicated,  
497  
498 pSGIE86 or Tat-expressing plasmids in 1:3 ratio, along with 0.25  $\mu$ g of pSV-Rluc plasmid as a  
499  
500 control for transfection efficiency. Total DNA amount was equalized with pSG5 empty vector.  
501  
502 After incubation for 4 h at 37°C, the transfection mixtures were removed and medium containing  
503  
504 either BBR or DMSO (0.1%) as a control was added to the cells. To investigate whether BBR could  
505  
506 affect the transactivation of MCMV *E1* gene promoter by the IE3 protein, NIH 3T3 cells grown on  
507  
508 24-well plates were co-transfected using Lipofectamine 3000 with 0.75  $\mu$ g of luciferase reporter  
509  
510 plasmid pGL3-E1 and, where indicated, with 1.5  $\mu$ g of pIE3 plasmid and with 0.15  $\mu$ g pRL-TK  
511  
512 plasmid. In control transfections, the total amount of DNA was equalized with pBSK. After 3 h at  
513  
514 37°C, transfected cells were treated with 50  $\mu$ M BBR, or 50  $\mu$ M WC5 as a positive control, or 0.1%  
515  
516 DMSO (v/v) as a negative control. At 48 h post-transfection, cells were harvested for the  
517  
518 measurement of firefly and *Renilla* luciferase activities. For all transfection experiments, firefly and  
519  
520 *Renilla* luciferase activities were measured using the Dual-Luciferase reporter assay system kit  
521  
522 (Promega).  
523  
524  
525  
526  
527

## 528 2.10 Statistical analysis

529  
530  
531

532  
533  
534 All statistical analyses were performed using GraphPad Prism version 5.00 for Windows  
535  
536 (www.graphpad.com; GraphPad Software, San Diego, CA).  
537

### 538 539 540 541 **3. Results**

#### 542 543 *3.1 Berberine exerts broad-spectrum anti-HCMV activity*

544  
545 In a drug repurposing screening specifically designed to identify inhibitors of the HCMV  
546 transcription factor IE2, we identified the bioactive plant-derived BBR as a hit compound  
547  
548 (Mercorelli et al., 2016). The observation of the anti-HCMV activity of BBR in our experimental  
549 setting prompted us to characterize deeper its mechanism of action. To this end, we first confirmed  
550  
551 the anti-HCMV activity and cytotoxicity of BBR in HFF cells by PRAs and MTT assays,  
552  
553 respectively (Table 1). According to our previous observations (Mercorelli et al., 2016), BBR  
554  
555 specifically inhibited HCMV AD169 replication in a dose-dependent manner (Fig. 1) with an  
556  
557 Effective Concentration (EC<sub>50</sub>) of 2.65 μM. This value was very similar to that measured for GCV  
558  
559 in our experimental conditions (Table 1). The Cytotoxic Concentration (CC<sub>50</sub>) determined by MTT  
560  
561 assays was 390 μM, thus resulting in a favorable Selectivity Index (SI) of 147 (Table 1). In this  
562  
563 regard, a similar SI value was previously observed for BBR in MRC5 cells (Hayashi et al., 2007).  
564  
565 To further characterize the anti-HCMV activity of BBR, we performed PRAs with several HCMV  
566  
567 strains, including different low-passage clinical isolates (TB40-UL32-EGFP, VR1814, and  
568  
569 388438U). Results reported in Table 2 indicated that the anti-HCMV activity of BBR is not  
570  
571 dependent on the viral strain used for the studies, since the EC<sub>50</sub> values obtained with different  
572  
573 HCMV strains were all comparable.  
574  
575  
576  
577  
578  
579  
580

#### 581 *3.2 Activity of BBR against drug-resistant HCMV strains*

582  
583 Next, we evaluated the activity of BBR against HCMV strains resistant to the available viral  
584  
585 DNA polymerase inhibitors, as the emergence of drug resistance is an increasing cause of transplant  
586  
587 failure associated with HCMV infections, in particular after prolonged antiviral therapy (Razonable,  
588  
589  
590

591  
592  
593 2018). BBR fully inhibited the replication of viruses with mutations in *UL54* gene conferring cross-  
594 resistance to GCV and CDV and to FOS and acyclovir (strains GDG<sup>r</sup>P53 and PFA<sup>r</sup>D100,  
595 respectively, Table 3). These results suggested that BBR may have a mechanism of action that  
596 differs from that of the currently available anti-HCMV drugs that target the viral DNA polymerase.  
597  
598  
599

### 600 601 602 603 604 *3.3 BBR inhibits HCMV DNA replication*

605  
606 To investigate the effect of BBR on the replication of HCMV genome, we performed a  
607 quantitative analysis of viral DNA production at different times p.i.. As depicted in Fig. 2, a  
608 progressive increase of viral DNA levels was detected by qPCR in a time-dependent manner up to  
609 120 h p.i. in untreated infected cells. In contrast, already at 72 h p.i. (i.e., after a completed cycle of  
610 replication), BBR, like the specific HCMV DNA polymerase inhibitor GCV, significantly inhibited  
611 the replication of viral genome. The inhibitory activity of BBR was confirmed later at 96 and 120 h  
612 p.i. (Fig. 2). Thus, most likely BBR affects a stage of the HCMV replication cycle that is located  
613 prior to the onset of viral DNA replication and this interference resulted in a significant impairment  
614 of viral DNA synthesis.  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628

### 629 *3.4 BBR interferes with the HCMV replication cycle after the IE phase*

630  
631 To determine whether the observed inhibition of HCMV DNA synthesis (Fig. 2) was a  
632 consequence of a BBR-mediated effect on viral IE and/or E gene expression that foreruns viral  
633 genome replication, HFFs were infected with HCMV AD169 and treated with BBR for different  
634 times p.i. Then, total protein cell extracts were assayed by immunoblotting for the content of  
635 representative Immediate-Early (IE1 and IE2), Early (UL44), and Late (UL99) viral proteins  
636 (Figure 3). For each time p.i. analyzed, control samples were: (i) extracts prepared from AD169-  
637 infected cells treated with the appropriate DMSO amount, and (ii) AD169-infected cells treated  
638 with NTZ, as a positive control for inhibition of the expression of Early and Late HCMV proteins  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649

650  
651  
652 (Mercorelli et al., 2016). Figure 3 shows that BBR did not seemingly affect IE1 and IE2 protein  
653 accumulation at each time analyzed. In contrast, compared to the untreated cells, BBR determined a  
654 clear reduction in UL44 and UL99 levels, although less markedly than NTZ, which was used as a  
655 positive control. Taken together, these results indicated that BBR affects HCMV replication cycle  
656 after the expression of IE proteins and, together with those reported in Fig. 2, suggested that BBR  
657 likely interferes with a molecular event involved in the expression of HCMV E genes.  
658  
659  
660  
661  
662  
663  
664  
665  
666

### 667 *3.5 BBR inhibits the IE2-dependent transactivation of both viral and cellular promoters*

668

669 To investigate whether BBR might affect the transactivation of E genes of HCMV,  
670 luciferase reporter plasmids containing full-length or a minimal *UL54* gene promoter were  
671 transfected in HELFs. The *UL54* promoter is a prototypic HCMV E gene promoter that is  
672 transactivated by IE2, thus its activation marks out the E phase of HCMV replicative cycle (Stinski  
673 & Petrik, 2008). Two luciferase reporter plasmids containing different segments of the *UL54* gene  
674 5'-flanking region were used: the UL54-0.4 construct includes the full-length gene promoter, while  
675 the UL54-0.15 plasmid carries a segment of 150 bp upstream from the transcription start site  
676 (Gariano et al., 2012). This shorter portion of the *UL54* 5'-flanking region mediates the IE2-  
677 dependent transactivation of the *UL54* gene at a level comparable to that of the full-length  
678 promoter. Furthermore, it includes an 8-bp inverted repeat element 1 (IR-1, located between -55 and  
679 -48 nt relative to the transcription start site) which has been shown to be required for both HCMV-  
680 and IE2-mediated transactivation (Kerry et al. 1996). Thus, to identify the minimal portion of the  
681 *UL54* gene promoter sufficient to mediate the sensitivity to BBR, the UL54-0.15 construct was also  
682 included in transfection-transduction experiments. At 24 h post-transfection, HELFs were  
683 transduced with the adenoviral vectors AdVIE2 or AdVLacZ as a negative control of transcriptional  
684 activation, and, after additional 2h, treated with BBR, ISIS 2922, or NTZ. The latter two  
685 compounds were employed as positive controls for inhibition of the IE2-dependent *UL54* gene  
686 promoter transactivation (Mercorelli et al., 2016). As shown in Fig. 4A, ectopic expression of IE2  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708

709 significantly increased the transcriptional activity of both *UL54* reporter constructs compared to  
710  
711 cells expressing LacZ. As expected, both NTZ and ISIS 2922, both used as a positive control,  
712  
713 inhibited the IE2-dependent transactivation of the *UL54*-0.4 promoter by 87% and 95%,  
714  
715  
716 respectively (Mercorelli et al., 2016). Interestingly, also treatment with BBR decreased the  
717  
718 transcriptional activity of the full-length *UL54*-0.4 promoter by 77% and that of the minimal  
719  
720 promoter *UL54*-0.15 by about 65% (Fig. 4A). These data indicated the ability of at BBR to interfere  
721  
722 with the IE2-dependent transactivation of the promoter of an essential viral E gene, and that a  
723  
724 segment of 150 bp upstream from the *UL54* transcription initiation site is sufficient to mediate the  
725  
726 inhibitory activity of BBR.  
727  
728

729  
730 The above observation then prompted the investigation on the effect of BBR on the activation of  
731  
732 other gene promoters that can be activated by IE2. Cellular cyclin E (*CycE*) gene expression is up-  
733  
734 regulated upon HCMV infection in quiescent cells to promote G0/G1 transition and its  
735  
736 transcriptional activation can be directly stimulated by IE2 (Bresnahan et al., 1998). To assess the  
737  
738 effect of BBR on the IE2-mediated transactivation of *CycE* gene promoter, we co-transfected  
739  
740 permissive U373-MG cells with a construct expressing IE2 together with reporter constructs  
741  
742 containing either a portion of wt *CycE* promoter (pCycE) or a mutated version wherein the binding  
743  
744 sites for the cellular transcription factor E2F at -16 and +7 have been mutated (mpCycE). As shown  
745  
746 in Fig. 4B, BBR efficiently inhibited the IE2-dependent transactivation of the pCycE. Similar  
747  
748 results were obtained in cells transfected with mpCyE construct, thus indicating that disruption of  
749  
750 E2F binding sites of the *CycE* gene promoter did not affect the inhibitory activity exerted by BBR  
751  
752 (Fig. 4C).  
753  
754

755  
756 Taken together, these results suggest that BBR affects the transactivation of both viral and  
757  
758 cellular promoters, which are known to depend on IE2 for their activation.  
759  
760

### 761 762 *3.6 BBR is not a general inhibitor of viral and cellular transcription* 763 764 765 766 767

768  
769  
770 To investigate whether the inhibitory effect of BBR was specific for IE2 and not due to a  
771 general inhibition of transcription, the activities of two other viral promoters, i.e., the MIEP of  
772 HCMV and the LTR of HIV-1, which contain multiple binding sites for general cellular  
773 transcription factors, were examined for their sensitivity to BBR. Although an inhibitory activity of  
774 BBR on the basal activity of both viral promoters was observed (Fig. 5A), it was not as solid or  
775 dose responsive as that measured on the IE2-dependent transactivation of both *UL54* and *CycE* gene  
776 promoters (Fig. 4). Moreover, since the HIV-1 LTR can be specifically transactivated by the virus-  
777 encoded Tat transcription factor (Ne et al., 2018), we also investigated the effect of BBR on the Tat-  
778 mediated transactivation of LTR. As shown in Figure 5B, BBR did not affect the Tat-mediated  
779 transactivation of HIV-1 LTR. These results thus suggest that most likely BBR is not a general  
780 inhibitor of transcription.  
781  
782

793 Then, to further strengthening the specificity of IE2 inhibition by BBR, we evaluated its  
794 effect on the activity of the other major HCMV-encoded IE transcription factor, IE1. IE1 and IE2  
795 proteins originate from a single precursor RNA through alternative splicing, therefore IE1 shares  
796 the same first three exons (85 aa) with IE2 (Stinski and Petrik, 2008). We previously reported that  
797 IE1 transactivates the human thymidylate synthase (TS) gene promoter to stimulate cellular TS  
798 activity that is required for HCMV DNA replication in quiescent cells (Gribaudo et al., 2002).  
799 Based on this premise, we investigated the effects of BBR on the IE1-dependent transactivation of  
800 the human *TS* gene promoter. To this end, HELFs cells were co-transfected with pHTS-243/+30 and  
801 an IE1 expression vector. As reported in Fig. 5C, IE1-dependent transactivation of the human *TS*  
802 promoter was not affected by the treatment with BBR. NTZ, included as a control of a specific  
803 inhibitor of the IE2-mediated transactivation, did not affect the IE1-mediated activation of cellular  
804 *TS* gene promoter as previously observed (Mercorelli et al., 2016).  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818

819 Altogether, these results indicate that the observed BBR-mediated inhibition of IE2-  
820 dependent transactivating activity is not due to a general inhibitory effect on transcription.  
821 Moreover, together with those reported in Fig. 4, they sustain the hypothesis that the overall  
822  
823  
824  
825  
826

827  
828  
829 inhibitory activity of BBR against HCMV likely stems from its ability to interfere with the  
830 expression of critical E genes required for viral DNA synthesis and progression of HCMV  
831 replication cycle.  
832  
833  
834  
835  
836  
837

### 838 *3.7 BBR prevents murine CMV replication and inhibits the IE3-dependent transactivation of the* 839 *Early E1 gene promoter*

840  
841  
842 Finally, we evaluated the activity of BBR also against murine CMV (MCMV). To this end,  
843 PRAs were performed in NIH 3T3 fibroblasts infected with the Smith strain of MCMV. As reported  
844 in Table 4, BBR fully retained antiviral activity against MCMV and the measured EC<sub>50</sub> values were  
845 comparable to those obtained for the HCMV strains (Tables 1 to 3). Moreover, BBR did not show  
846 any significant cytotoxicity in uninfected cells, confirming that the inhibition of the virus replication  
847 was due to a specific antiviral effect.  
848  
849  
850  
851  
852  
853

854  
855 Having established that BBR is also active against MCMV, we wondered whether the  
856 mechanism of action of BBR against MCMV may be the same observed for the human virus. To  
857 this end, NIH 3T3 cells were transfected with an indicator plasmid containing the luciferase gene  
858 driven by the prototypic MCMV Early *E1* gene promoter (pGL3-E1), together with an IE3-  
859 expressing vector (pIE3). The MCMV IE3 protein is the structural and functional homolog of  
860 HCMV IE2 (Messerle et al., 1992). Transfected NIH 3T3 cells were then treated with BBR or  
861 WC5, used as a control for inhibition of MCMV E1 promoter (Mercorelli et al., 2014). As shown in  
862 Fig. 6, the expression of IE3 increased the activity of the *E1* gene promoter of more than 50-fold.  
863 Treatment with BBR reduced the IE3-dependent transactivation of the *E1* gene promoter by 60%  
864 compared to that of DMSO-treated cells. As expected, WC5 reduced the luciferase activity by 71%  
865 (Mercorelli et al., 2014). These results thus indicated that the mechanism of action of BBR against  
866 HCMV is conserved also against MCMV.  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882

## 883 **4. Discussion**

884  
885



886  
887  
888  
889 The identification and validation of new antiviral molecules to prevent or limit HCMV  
890 replication remains a priority for the clinical management of HCMV infections. Since IE2 plays a  
891 critical role in the progression of HCMV replication, as well in virus pathogenesis and reactivation  
892 from latency (Scholz et al., 2001; Stinski and Petrik, 2008), we and others have addressed the  
893 identification and characterization of small molecules that could block IE2 synthesis or activities  
894 (Mercorelli et al., 2014a, b; Gardner et al., 2015; Mercorelli et al., 2016; Beelontally et al., 2017;  
895 Mercorelli et al., 2018a). In a drug repurposing screen devised to select early inhibitors of HCMV  
896 replication, we previously identified 38 different molecules active in the inhibition of HCMV E  
897 gene expression (Mercorelli et al., 2016). To date, some of them have been confirmed to selectively  
898 inhibit the IE2-mediated transactivation of essential viral E genes and hence HCMV replication  
899 (Mercorelli et al., 2016; Mercorelli et al., 2018a). Here, we add another piece of knowledge about  
900 this novel class of IE2 inhibitors by reporting the characterization of the mechanism of action of  
901 BBR, one of the compounds selected in the drug repurposing screen for its anti-HCMV activity.  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915

916 BBR is an isoquinoline alkaloid present in several medicinal plants including *Berberis*  
917 *vulgaris*, *Coptis chinensis*, *Hydrastis canadensis*, and *Rhizoma coptidis*, and over the past years  
918 several biological effects of BBR have been reported, including antimicrobial activities against  
919 bacteria, fungi, and viruses (Imenshahidi and Hosseinzadeh, 2016; Kumar et al., 2015). In this  
920 regard, an inhibitory activity of BBR against the replication of HCMV (strain not specified) was  
921 previously reported (Hayashi et al., 2007); however, the mechanism by which BBR impaired  
922 HCMV replication was not defined. In the present study, we have demonstrated that BBR is a  
923 broad-spectrum inhibitor of HCMV replication, including strains resistant to drugs that target viral  
924 DNA polymerase, thus suggesting that its mechanism of action differs from that of the currently  
925 used DNA polymerase inhibitors. To support further this hypothesis, we showed that BBR  
926 selectively reduced the expression of representative E and L viral proteins, without affecting that of  
927 IE proteins, and inhibited the synthesis of viral DNA as well, thus suggesting that these inhibitory  
928 effects of BBR most likely account for its marked overall antiviral activity on HCMV replication.  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944

945  
946  
947 Based on these facts, we hypothesized that BBR could target a molecular event involved in the  
948  
949 switch from IE to E phase of virus replication cycle. Indeed, BBR strongly reduced the ability of  
950  
951 IE2 to transactivate two different versions of a prototypic E gene promoter, i.e., the *UL54* gene  
952  
953 promoter. Although other molecular mechanisms cannot be totally ruled out, the effect of BBR  
954  
955 seems to be specific for the IE2 transactivating activity, since we observed that: i) it inhibited the  
956  
957 activation of gene promoters of both viral and cellular origin that depend on IE2 for their  
958  
959 transcriptional activity (Fig. 4); ii) it did not significantly affect neither the transcriptional activity  
960  
961 of viral gene promoters responsive to general cellular transcription factors, nor the Tat-dependent  
962  
963 transactivation of HIV-1 LTR (Fig. 5); and iii) it did not exert any interference with the  
964  
965 transactivating activity of the closely related IE1 protein (Fig. 5), which shares 85 N-terminal  
966  
967 residues with IE2 (Stinski and Petrik, 2008).  
968  
969

970  
971 Among molecules targeting IE2, BBR acts differently from fomivirsen, the only IE2  
972  
973 inhibitor that had been approved for the treatment of HCMV infections so far (Britt and Prichard,  
974  
975 2018), since unlike the latter it does not inhibit the expression of IE2 (Fig. 3). BBR in fact interferes  
976  
977 with the transactivating properties of IE2 (Fig. 4), and therefore, along with NTZ (Mercorelli et al.,  
978  
979 2016), it belongs to a novel class of anti-HCMV agents that can act by interfering with the  
980  
981 transactivating activity of IE2.  
982

983  
984 It is known that BBR can modulate multiple host cell signaling pathways, including NF- $\kappa$ B (Pandey  
985  
986 et al., 2008) and mitogen activated protein kinases (MAPK) (Cui et al., 2009). Since these pathways  
987  
988 are also activated by HCMV infection and contribute to the efficient viral gene expression and  
989  
990 progression of HCMV replicative cycle (Johnson et al., 2000; DeMeritt et al., 2004; Caposio et al.,  
991  
992 2007; Caposio et al., 2010), it is possible that BBR may hinder the full activation of these  
993  
994 transduction pathways in HCMV-infected cells, thus leading to a significant impairment of viral  
995  
996 replication. In this regard, Song *et al.* observed that BBR inhibits HSV IE protein expression when  
997  
998 added on cells *before* HSV infection (Song et al., 2014). This inhibition was associated to an  
999  
1000 impairment of HSV-induced NF- $\kappa$ B activation, indicating that BBR compromises a very early stage  
1001  
1002  
1003

1004  
1005  
1006 of the HSV replication cycle, such as the IE gene expression. The NF- $\kappa$ B pathway is activated very  
1007  
1008 early also by HCMV infection and is required to kick-start the viral IE gene expression (Caposio et  
1009  
1010 al., 2007). However, it is unlikely that BBR could affect NF- $\kappa$ B activation in HCMV-infected cells,  
1011  
1012 since we did not observe any significant effect on the accumulation of IE proteins (Fig. 3), whose  
1013  
1014 expression is driven by the Major IE Promoter (MIEP) of HCMV that contains four NF- $\kappa$ B sites  
1015  
1016 (Stinski and Meier, 2007). Moreover, in different virus models, such as those of influenza and Zika  
1017  
1018 viruses, it has been observed that BBR affects virus replication after the initial attachment and entry  
1019  
1020 (Cecil et al., 2011; Robinson et al., 2018).  
1021  
1022

1023  
1024 BBR is also a known inhibitor of MAPKs pathway, in particular ERK1/2 and p38 kinases (Cui et  
1025  
1026 al., 2009; Shin et al., 2015; Varghese et al., 2016b). Relevant to this activity of BBR, it is well  
1027  
1028 established that HCMV activates several MAPKs, including ERK1/2 and p38 (Johnson et al., 2000;  
1029  
1030 Caposio et al., 2010), and that an appropriate phosphorylation of MAPKs downstream partners in  
1031  
1032 HCMV-infected cells is required for efficient progression of the viral replicative cycle (Johnson et  
1033  
1034 al., 2001). Given that IE2 can be phosphorylated by MAPKs *in vitro* (Harel and Alwine, 1998), and  
1035  
1036 the phosphorylation status modulates IE2-dependent transcriptional activation of gene promoters  
1037  
1038 (Barrasa et al., 2005), one could hypothesize that the inhibitory activity of BBR on the IE2-  
1039  
1040 dependent transactivation of E genes may descend from its ability to hamper MAPKs activation.  
1041  
1042 Noteworthy, the block of MAPKs pathway was recently identified as the mechanism of the antiviral  
1043  
1044 activity of BBR against RSV and alphaviruses (Shin et al., 2015; Varghese et al., 2016b). Relevant  
1045  
1046 to the above hypothesis, it is worth mentioning that the p38 kinase inhibitor FHPI was reported to  
1047  
1048 halt HCMV replicative cycle after IE gene expression and prior to the onset of viral DNA  
1049  
1050 replication (Johnson et al., 1999), thus in the same time frame of the HCMV replication cycle that  
1051  
1052 we identified as the main target of the antiviral activity of BBR (Fig. 3). Clearly, further  
1053  
1054 experimentation is required to confirm this hypothesis and it will be object of future studies.  
1055  
1056

1057  
1058 BBR is active against a broad range of different microbial pathogens (Kumar et al., 2015), thus it  
1059  
1060 may offer advantages over other current anti-HCMV drugs, since HCMV infection can increase the  
1061  
1062

1063  
1064  
1065 risk in immunosuppressed patients of other opportunistic infections, such as bacterial and fungal  
1066  
1067 infections. Moreover, BBR shows very low toxicity and side effects (Pang et al., 2015) and these  
1068  
1069 features, together with the other pharmacological properties, point out BBR as an interesting  
1070  
1071 candidate to develop alternative anti-HCMV therapeutic strategies.  
1072  
1073

## 1074 1075 1076 **5. Conclusion**

1077  
1078 In conclusion, the results of this study suggest BBR as another attractive candidate for a new  
1079  
1080 class of anti-HCMV drugs that exert their effects via novel pathways that target IE2 functions, and  
1081  
1082 warrant further investigations to evaluate whether BBR may be effective in animal models of CMV  
1083  
1084 infection. Indeed, BBR is active also against MCMV replication and prevents the transactivation of  
1085  
1086 a prototypic MCMV E gene mediated by the IE3 protein, the murine homolog of HCMV IE2.  
1087  
1088 Given this high similarity between HCMV IE2 and MCMV IE3, the investigation of the therapeutic  
1089  
1090 potential of BBR in the murine model of CMV infection is worth pursuing.  
1091  
1092  
1093  
1094

## 1095 **Funding**

1096  
1097 This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, grant n.  
1098  
1099 IG18855) to A. Loregian; by the University of Padua (Progetto di Ricerca di Ateneo 2014, grant no.  
1100  
1101 PDA141311) to A. Loregian, by FINDER STARS Consolidator Grant to B.M., and by the  
1102  
1103 University of Torino (Ricerca Locale) to A. Luganini and G.G. Funding sources had no role in  
1104  
1105 experimental design, data collection, data interpretation or the decision to submit the work for  
1106  
1107 publication.  
1108  
1109  
1110  
1111

## 1112 **Declaration of interest**

1113  
1114 All authors declare no conflicts of interest.  
1115  
1116  
1117

## 1118 **Acknowledgments**

1119  
1120  
1121

1122  
1123  
1124 We thank C. Sinzger (University of Ulm, Germany) for HCMV TB40-UL32-EGFP, and G. Gerna  
1125 (IRCCS Policlinico San Matteo, Pavia, Italy) for HCMV VR1814. We are grateful to E.A.  
1126  
1127  
1128 Thompson, S. Richter, and A. Caputo for providing plasmids used in this study.  
1129  
1130  
1131  
1132

## 1133 **References**

1134  
1135 Barrasa, M.I., Harel, N.Y., Alwine, J.C., 2005. The phosphorylation status of the serine-rich region  
1136 of the human cytomegalovirus 86-kilodalton major immediate-early protein IE2/IEP86 affects  
1137 temporal viral gene expression. *J. Virol.* 79, 1428-1437.  
1138

1139 Beelontally, R., Wilkie, G.S., Lau, B., Goodmaker, C.J., Ho, C.M.K., Swanson, C.M., Deng, X.,  
1140 Wang, J., Gray, N.S., Davison, A.J., Strang, B.L., 2017. Identification of compounds with anti-  
1141 human cytomegalovirus activity that inhibit production of IE2 proteins. *Antivir. Res.* 138, 61-67.  
1142

1143 Bray, M., Andrei, G., Ballana, E., Carter, K., Durantel, D., Gentry, B., Janeba, Z., Moffat, J.,  
1144 Oomen, C.J., Tarbet, B., Riveira-Munoz, E., Este, J.A., International Society for Antiviral Research  
1145 2018. Meeting report: 31st International Conference on Antiviral Research. *Antivir. Res.* 158, 88-  
1146 102.  
1147

1148  
1149 Bresnahan, W.A., Albrecht, T., Thompson, E.A., 1998. The cyclin E promoter is activated by  
1150 human cytomegalovirus 86-kDa immediate early protein. *J. Biol. Chem.* 273:22075-22082.  
1151

1152 Britt, W.J., 2018. Maternal immunity and the natural history of congenital human cytomegalovirus  
1153 infection. *Viruses* 10, pii: E405.  
1154

1155 Britt, W.J., and Prichard, M.N., 2018. New therapies for human cytomegalovirus infections.  
1156 *Antivir. Res.* 159:153-174.  
1157

1158 Caposio, P., Luganini, A., Hahn, G., Landolfo, S., Gribaudo, G., 2007. Activation of the virus-  
1159 induced IKK/NF-kappaB signalling axis is critical for the replication of human cytomegalovirus in  
1160 quiescent cells. *Cell. Microbiol.* 9, 2040-2054.  
1161

1162 Caposio, P., Luganini, A., Bronzini, M., Landolfo, S., Gribaudo, G. 2010. The Elk-1 and Serum  
1163 Response Factor binding sites in the Major Immediate-Early promoter of human cytomegalovirus  
1164 are required for efficient viral replication in quiescent cells and compensate for inactivation of the  
1165 NF-κB sites in proliferating cells. *J. Virol.*, 84, 4481-4493.  
1166  
1167

1168 Cavaletto, N., Luganini, A., Gribaudo, G. 2015. Inactivation of the human cytomegalovirus US20  
1169 gene hampers productive viral replication in endothelial Cells. *J. Virol.* 89, 11092–11106.  
1170

1171 Cecil, C.E., Davis, J.M., Cech, N.B., Laster, S.M., 2011. Inhibition of H1N1 influenza A virus  
1172 growth and induction of inflammatory mediators by the isoquinoline alkaloid berberine and extracts  
1173 of goldenseal (*Hydrastis canadensis*). *Int. Immunopharmacol.* 11, 1706-1714.  
1174

1175 Cui, G., Qin, X., Zhang, Y., Gong, Z., Ge, B., Zang, Y.Q., 2009. Berberine differentially modulates  
1176 the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type  
1177 1 diabetic mice. *J. Biol. Chem.* 284, 28420-28429.  
1178  
1179  
1180

1181  
1182  
1183  
1184 DeMeritt, I.B., Milford, L.E., Yurochko, A.D., 2004. Activation of the NF-kappaB pathway in  
1185 human cytomegalovirus-infected cells is necessary for efficient transactivation of the major  
1186 immediate-early promoter. *J. Virol.* 78, 4498-4507.  
1187

1188  
1189 Gardner, T.J., Cohen, T., Redmann, V., Lau, Z., Felsenfeld, D., Tortorella, D., 2015. Development  
1190 of a high-content screen for the identification of inhibitors directed against the early steps of the  
1191 cytomegalovirus infectious cycle. *Antivir. Res.* 113, 49-61.  
1192

1193 Gariano, G.R., Dell'Oste, V., Bronzini, M., Gatti, D., Luganini, A., Andrea, M.D., Gribaudo, G.,  
1194 Gariglio, M., Landolfo, S., 2012. The intracellular DNA sensor IFI16 gene acts as restriction factor  
1195 for human cytomegalovirus replication. *PLoS Pathog.* 8, e1002498.  
1196

1197 Gibellini, D., Caputo, A., Celeghini, C., Bassini, A., La Placa, M., Capitani, S., Zauli, G., 1995. Tat-  
1198 expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute  
1199 human immunodeficiency virus-type 1 (HIV-1) infection. *Br. J. Haematol.* 89, 24-33.  
1200

1201 Gribaudo, G., Riera, L., Rudge, T.L., Caposio, P., Johnson, L.F., Landolfo, S., 2002. Human  
1202 cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent  
1203 fibroblasts. *J. Gen. Virol.* 83, 2983-2993.  
1204

1205 Griffiths, P., Baraniak, I., Reeves, M., 2015. The pathogenesis of human cytomegalovirus. *J. Pathol.*  
1206 235, 288-297.  
1207

1208 Haidar, G., Singh, N., 2017. Viral infections in solid organ transplant recipients: novel updates and  
1209 a review of the classics. *Curr. Opin. Infect. Dis.* 30, 579-588.  
1210

1211 Harel, N.Y., Alwine, J.C., 1998. Phosphorylation of the human cytomegalovirus 86-kilodalton  
1212 immediate-early protein IE2. *J. Virol.* 72, 5481-5492.  
1213

1214 Hayashi, K., Minoda, K., Nagaoka, Y., Hayashi, T., Uesato, S., 2007. Antiviral activity of berberine  
1215 and related compounds against human cytomegalovirus. *Bioorg. Med. Chem. Lett.* 17, 1562-1564.  
1216

1217 Imenshahidi, M., Hosseinzadeh, H., 2016. *Berberis vulgaris* and berberine: An update review.  
1218 *Phytother. Res.* 30, 1745-1764.  
1219

1220 Johnson, R.A., Huong, S.M., Huang, E.S., 1999. Inhibitory effect of 4-(4-fluorophenyl)-2-(4-  
1221 hydroxyphenyl)-5-(4-pyridyl)1H-imidazole on HCMV DNA replication and permissive infection.  
1222 *Antiv. Res.* 41, 101-111.  
1223

1224 Johnson, R.A., Huong, S.M., Huang, E.S., 2000. Activation of the mitogen-activated protein kinase  
1225 p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for  
1226 activation of p38. *J. Virol.* 74, 1158-1167.  
1227

1228 Johnson, R.A., Ma, X.L., Yurochko, A.D., Huang, E.S., 2001. The role of MKK1/2 kinase activity  
1229 in human cytomegalovirus infection. *J. Gen. Virol.* 82, 493-497.  
1230

1231 Kerry, J.A., Priddy, M.A., Jerve, T.Y., Kohler, C.P., Staley, T.L., Vanson, C.D., Jones, T.R.,  
1232 Iskenderian, A.C., Anders, D.G., Stenberg, R.M. 1996. Multiple regulatory events influence human  
1233 cytomegalovirus DNA polymerase (UL54) expression during viral infection. *J. Virol.* 70, 373-382.  
1234  
1235  
1236  
1237  
1238  
1239

- 1240  
1241  
1242 Klucher, K.M., Sommer, M., Kadonaga, J.T., Spector, D.H., 1993. In vivo and in vitro analysis of  
1243 transcriptional activation mediated by the human cytomegalovirus major immediate-early proteins.  
1244 Mol. Cell. Biol. 13, 1238-1250.  
1245
- 1246 Kumar, A., Ekavali, Chopra, K., Mukherjee, M., Pottabathini, R., Dhull, D.K., 2015. Current  
1247 knowledge and pharmacological profile of berberine: An update. Eur. J. Pharmacol. 761, 288-297.  
1248  
1249
- 1250 Loregian, A., Coen, D.M., 2006. Selective anti-cytomegalovirus compounds discovered by  
1251 screening for inhibitors of subunit interactions of the viral polymerase. Chem. Biol.13, 191-200.  
1252
- 1253 Loregian, A., Mercorelli, B., Muratore, G., Sinigalia, E., Pagni, S., Massari, S., Gribaudo, G., Gatto,  
1254 B., Palumbo, M., Tabarrini, O., Cecchetti, V., Palù, G., 2010. The 6-aminoquinolone WC5 inhibits  
1255 human cytomegalovirus replication at an early stage by interfering with the transactivating activity  
1256 of viral immediate-early 2 protein. Antimicrob. Agents Chemother. 54, 1930-1940.  
1257
- 1258 Luganini, A., Caposio, P., Mondini, M., Landolfo, S., Gribaudo, G., 2008. New cell-based indicator  
1259 assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral  
1260 immediate-early 2 protein activity. J. Appl. Microbiol. 105, 1791-1801.  
1261
- 1262 Luganini, A., Terlizzi, M.E., Gribaudo, G., 2016. Bioactive molecules released from cells infected  
1263 with the human cytomegalovirus. Front. Microbiol. 7:715.  
1264
- 1265 Martinez, F.P., Cosme, R.S.C., Tang, Q., 2010. Murine cytomegalovirus major immediate-early  
1266 protein 3 interacts with cellular and viral proteins in viral DNA replication compartments and is  
1267 important for early gene activation. J. Gen. Virol. 91, 2664-2676.  
1268  
1269
- 1270 Marty, F.M., Ljungman, P., Chemaly, R.F., Maertens, J., Dadwal, S.S., Duarte, R.F., Haider, S.,  
1271 Ullmann, A.J., Katayama, Y., Brown, J., Mullane, K.M., Boeckh, M., Blumberg, E.A., Einsele, H.,  
1272 Snyderman, D.R., Kanda, Y., DiNubile, M.J., Teal, V.L., Wan, H., Murata, Y., Kartsonis, N.A.,  
1273 Leavitt, R.Y., Badshah, C., 2017. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell  
1274 transplantation. N. Engl. J. Med. 377, 2433-2444.  
1275
- 1276 Meesing, A., Razonable, R.R., 2018. New developments in the management of cytomegalovirus  
1277 infection after transplantation. Drugs 78, 1085-1103.  
1278
- 1279 Mercorelli, B., Gribaudo, G., Palu`, G., and Loregian, A. 2014a. Approaches for the generation of  
1280 new anti-cytomegalovirus agents: identification of protein protein interaction inhibitors and  
1281 compounds against the HCMV IE2 protein. Methods Mol. Biol. 1119, 349-363.  
1282
- 1283 Mercorelli, B., Lembo, D., Palu, G., Loregian, A., 2011. Early inhibitors of human  
1284 cytomegalovirus: state-of-art and therapeutic perspectives. Pharmacol. Ther. 131, 309-329.  
1285  
1286
- 1287 Mercorelli, B., Luganini, A., Celegato, M., Palù, G., Gribaudo, G., Loregian, A., 2018a.  
1288 Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early  
1289 inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein. Antivir. Res.  
1290 150, 130-136.  
1291
- 1292 Mercorelli, B., Luganini, A., Muratore, G., Massari, S., Terlizzi, M.E., Tabarrini, O., Gribaudo, G.,  
1293 Palù, G., Loregian, A., 2014b. The 6-Aminoquinolone WC5 inhibits different functions of the  
1294 immediate-early 2 (IE2) protein of human cytomegalovirus that are essential for viral replication.  
1295 Antimicrob. Agents Chemother. 58, 6615-6626.  
1296  
1297  
1298

1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357

Mercorelli, B., Luganini, A., Nannetti, G., Tabarrini, O., Palù, G., Gribaudo, G., Loregian, A., 2016. Drug repurposing approach identifies inhibitors of the prototypic viral transcription factor IE2 that block human cytomegalovirus replication. *Cell Chem. Biol.* 23, 340-351.

Mercorelli, B., Muratore, G., Sinigalia, E., Tabarrini, O., Biasolo, M.A., Cecchetti, V., Palù, G., Loregian, A., 2009. A 6-aminoquinolone compound, WC5, with potent and selective anti-human cytomegalovirus activity. *Antimicrob. Agents Chemother.* 53, 312-315.

Mercorelli, B., Palù, G., Loregian, A., 2018b. Drug repurposing for viral infectious diseases: How far are we? *Trends Microbiol.* 26, 865-876.

Messerle, M., Buhler, B., Keil, G.M., Koszinowski, U.H., 1992. Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3. *J. Virol.* 66, 27-36.

Ne, E., Palstra, R.J., Mahmoudi, T., 2018. Transcription: Insights from the HIV-1 promoter. *Int. Rev. Cell. Mol. Biol.* 335, 191-243.

Pandey, M.K., Sung, B., Kunnumakkara, A.B., Sethi, G., Chaturvedi, M.M., Aggarwal, B.B., 2008. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. *Cancer Res.* 68, 5370-5379.

Pang, B., Zhao, L.-H., Zhou, Q., Zhao, T.-Y., Wang, H., Gu, C.-J., Tong, X.-L., 2015. Application of berberine on treating type 2 diabetes mellitus. *Int. J. Endocrinol.* 2015, 905749.

Perrone, R., Nadai, M., Frasson, I., Poe, J.A., Butovskaya, E., Smithgall, T.E., Palumbo, M., Palù, G., Richter, S.N., 2013. A dynamic G-quadruplex region regulates the HIV-1 long terminal repeat promoter. *J. Med. Chem.* 56, 6521-6530.

Razonable, R.R., 2018. Drug-resistant cytomegalovirus: clinical implications of specific mutations. *Curr. Opin. Organ. Transplant.* 23, 388-394.

Revello, M.G., Lilleri, D., Zavattoni, M., Stronati, M., Bollani, L., Middeldorp, J.M., Gerna, G., 2001. Human cytomegalovirus immediate-early messenger RNA in blood of pregnant women with primary infection and of congenitally infected newborns. *J. Infect. Dis.* 184, 1078-1081.

Robinson, C.L., Chong, A.C.N., Ashbrook, A.W., Jeng, G., Jin, J., Chen, H., Tang, E.I., Martin, L.A., Kim, R.S., Kenyon, R.M., Do, E., Luna, J.M., Saeed, M., Zeltser, L., Ralph, H., Dudley, V.L., Goldstein, M., Rice, C.M., Cheng, C.Y., Seandel, M., Chen, S., 2018. Male germ cells support long-term propagation of Zika virus. *Nat. Commun.* 9, 2090.

Sampaio, K.L., Cavignac, Y., Stierhof, Y.D., Sinzger, C., 2005. Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. *J. Virol.* 79, 2754-2767.

Scholz, M., Doerr, H.W., Cinatl, J., 2001. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? *Antivir. Res.* 49, 129-145.



1358  
1359  
1360 Shin, H.-B., Choi, M.-S., Yi, C.-M., Lee, J., Kim, N.-J., Inn, K.-S., 2015. Inhibition of respiratory  
1361 syncytial virus replication and virus-induced p38 kinase activity by berberine. *Int.*  
1362 *Immunopharmacol.* 27, 65-68.  
1363

1364 Song, S., Qiu, M., Chu, Y., Chen, D., Wang, X., Su, A., Wu, Z., 2014. Downregulation of cellular  
1365 c-Jun N-terminal protein kinase and NF-kappaB activation by berberine may result in inhibition of  
1366 herpes simplex virus replication. *Antimicrob. Agents Chemother.* 58, 5068-5078.  
1367  
1368

1369 Stinski, M.F., Meier, J.L., 2007. Immediate-early viral gene regulation and function, in: Arvin, A.,  
1370 Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K. (Eds.),  
1371 *Human herpesviruses: biology, therapy, and immunoprophylaxis.* Cambridge: Cambridge  
1372 University Press; Chapter 17.  
1373

1374 Stinski, M.F., Petrik, D.T., 2008. Functional roles of the human cytomegalovirus essential IE86  
1375 protein. *Curr. Top. Microbiol. Immunol.* 325, 133-152.  
1376

1377 Varghese, F.S., Kaukinen, P., Glasker, S., Beshpalov, M., Hanski, L., Wennerberg, K., Kummerer,  
1378 B.M., Ahola, T., 2016a. Discovery of berberine, abamectin and ivermectin as antivirals against  
1379 chikungunya and other alphaviruses. *Antivir. Res.* 126, 117-124.  
1380

1381 Varghese, F.S., Thaa, B., Amrun, S.N., Simarmata, D., Rausalu, K., Nyman, T.A., Merits, A.,  
1382 McInerney, G.M., Ng, L.F.P., Ahola, T., 2016b. The Antiviral Alkaloid Berberine Reduces  
1383 Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling. *J. Virol.* 90, 9743-9757.  
1384  
1385

1386 Wang, H., Li, K., Ma, L., Wu, S., Hu, J., Yan, H., Jiang, J., Li, Y., 2017. Berberine inhibits  
1387 enterovirus 71 replication by downregulating the MEK/ERK signaling pathway and autophagy.  
1388 *Virol. J.* 14, 2.  
1389  
1390

## 1391 **Figure legends**

1392

1393 **Figure 1. BBR exerts a dose-dependent inhibition of HCMV AD169 replication.** HFFs were  
1394 infected with HCMV AD169 and then treated with different concentrations of BBR (from 0.01 to  
1395 100  $\mu$ M), and incubated at 37°C for 10 days. Data shown are expressed as a percentage of the  
1396 plaque number determined in treated samples with respect to the DMSO-treated and mock-infected  
1397 controls and represent the means  $\pm$  SD of three independent experiments performed in duplicate.  
1398  
1399

1400 **Figure 2. Berberine inhibits viral DNA synthesis in HCMV-infected cells.** Infected HFFs were  
1401 treated with 50  $\mu$ M BBR, 25  $\mu$ M GCV, or 0.1% DMSO as a control. At 24, 72, 96, and 120 h p.i.,  
1402 total DNA was extracted and qPCR was performed with appropriate *IE2* and  *$\beta$ -globin* primers.  
1403  
1404

1405 HCMV genomic copies were normalized to the cellular  *$\beta$ -globin* copies. Data shown are the means  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416

1417  
1418  
1419  $\pm$  SD of four independent experiments performed in duplicate. \* $p < 0.05$ ; \*\* $p < 0.01$  versus  
1420  
1421 calibrator sample (DMSO).  
1422

1423 **Figure 3. Berberine reduces the expression of E and L HCMV proteins.** HFFs were mock-  
1424  
1425 infected or infected with AD169 (MOI of 0.5 PFU/cell) and after 2 h of viral adsorption, cells were  
1426  
1427 treated with 50  $\mu$ M BBR, 30  $\mu$ M NTZ, or with 0.1% DMSO (added in mock-infected and virus-  
1428  
1429 infected samples). Total cell protein extracts were prepared at the indicated times p.i., fractionated  
1430  
1431 by SDS-PAGE, and analyzed by immunoblotting. Protein markers sizes are indicated in kilodaltons.  
1432  
1433

1434 **Figure 4. BBR inhibits the IE2-dependent transactivation of viral and cellular promoters.** (A)

1435 HELF cells were transfected with the luciferase reporter plasmids pUL54-0.4 or pUL54-0.15.  
1436  
1437

1438 Twenty-four hours later, transfected cells were transduced with AdvIE2 or AdvLacZ at a MOI of  
1439  
1440 20 PFU/cell and then treated with 50  $\mu$ M BBR, 30  $\mu$ M NTZ, 5  $\mu$ M ISIS 2922, or 0.1% DMSO.  
1441

1442 Luciferase reporter activity was measured 48 h later to determine promoter activation under the  
1443  
1444 different conditions. Data represent the means  $\pm$  SD from three independent experiments in  
1445  
1446 triplicate. The results were analyzed by one-way ANOVA with Bonferroni post-test correction for  
1447  
1448 multiple comparisons. \*\*\* $p < 0.0001$ ; versus calibrator sample (AdvIE2 + DMSO).  
1449

1450 (B) (C) U373-MG cells were transfected with either (B) pCycE wt or (C) mutated mpCycE  
1451  
1452 indicator constructs along with either the empty pSG5 plasmid or the IE2-expressing pSGIE86  
1453  
1454 (IE2) plasmid and treated for 48 h with 25 or 50  $\mu$ M BBR, or 0.1% DMSO as a control. Then,  
1455  
1456 activation of CycE promoters under the different conditions was determined. Data represent the  
1457  
1458 means  $\pm$  SD from four independent experiments in duplicate. The results were analyzed by one-way  
1459  
1460 ANOVA with Bonferroni post-test correction for multiple comparisons. \*\* $p < 0.005$ ; \* $p < 0.05$ ;  
1461  
1462 versus calibrator sample (pCycE or mpCycE + DMSO).  
1463  
1464  
1465

1466 **Figure 5. BBR is not a general inhibitor of transcription.** U373-MG cells were transfected with  
1467  
1468 either (A) HCMV MIEP or (B) HIV-1 LTR indicator constructs along with either the empty pSG5  
1469  
1470 plasmid or a Tat-expressing plasmid and treated for 48 h with 25 or 50  $\mu$ M BBR, or 0.1% DMSO as  
1471  
1472 a control. Then, promoter activation under the different conditions was determined. Data represent  
1473  
1474  
1475

1476  
1477  
1478 the means  $\pm$  SD from four independent experiments in duplicate. The results were analyzed by one-  
1479  
1480 way ANOVA with Bonferroni post-test correction for multiple comparisons versus the calibrator  
1481  
1482 sample (pMIEP + DMSO for panel A; LTR + DMSO or LTR + Tat + DMSO for panel B).  
1483

1484  
1485 (C) HELF cells were co-transfected with phTS-243/+30 reporter vector along with empty pSG5  
1486  
1487 vector or an IE1-expressing vector. At 18 h after transfection, cells were washed and treated with 50  
1488  
1489  $\mu$ M BBR, 30  $\mu$ M NTZ, or 0.1% DMSO (v/v) for 48 h. Then, phTS promoter activation under the  
1490  
1491 different conditions was determined. The data shown are the mean  $\pm$  SD of two experiments, each  
1492  
1493 performed in triplicate. Data were analyzed by an unpaired t-test. \*\*p < 0.001; versus calibrator  
1494  
1495 sample (phTS-243/+30 + pIE1 + DMSO).  
1496

1497 **Figure 6. BBR abrogates the IE3-dependent transactivation of the Early *E1* gene promoter of**  
1498  
1499 **MCMV.** NIH3T3 cells were transfected with a plasmid containing luciferase reporter gene under  
1500  
1501 the control of the *E1* promoter (pGL3-E1) or co-transfected with an IE3-expressing plasmid (pIE3)  
1502  
1503 and then treated with 50  $\mu$ M BBR, 50  $\mu$ M WC5, or 0.1% DMSO. After 48 h, *E1* promoter  
1504  
1505 activation under the different conditions was determined. Data shown are the means  $\pm$  SD from two  
1506  
1507 independent experiments in triplicate and were analyzed by an unpaired t-test. \*p < 0.01; \*\*p <  
1508  
1509 0.001; versus calibrator sample (pGL3-E1 + pIE3 + DMSO).  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534

**Table 1.** Antiviral activity of BBR against HCMV AD169.

Compound	EC <sub>50</sub> <sup>a</sup> (μM)	CC <sub>50</sub> <sup>b</sup> (μM)	SI <sup>c</sup>
BBR	2.65 ± 0.35	390 ± 10	147
GCV	2.5 ± 0.5	>500	>200

<sup>a</sup>50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs against HCMV AD169 in HFF cells. Reported values represent the means ± the SD of data derived from three independent experiments in triplicate.

<sup>b</sup>50% Cytotoxic Concentration, the compound concentration that results in 50% of cytotoxicity, as determined by MTT assays in HFF cells. Reported values represent the means ± the SD of data derived from at least three independent experiments performed in quadruplicate.

<sup>c</sup>SI, Selectivity Index (determined as CC<sub>50</sub>/EC<sub>50</sub>).

**Table 2.** Activity of BBR against different HCMV strains.

HCMV Strain	BBR EC <sub>50</sub> <sup>a</sup> (μM)	CC <sub>50</sub> <sup>b</sup> (μM)	SI <sup>c</sup>
TB40-UL32-EGFP	2.70 ± 1.13	390 ± 10	144
VR1814	4.00 ± 0.71	390 ± 10	98
388438U	1.30 ± 0.42	390 ± 10	300

<sup>a</sup>50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs in HFF cells. Reported values represent the means ± the SD of data derived from at least three independent experiments in triplicate.

<sup>b</sup>50% Cytotoxic Concentration, the compound concentration that results in 50% of cytotoxicity, as determined by MTT assays in HFF cells. Reported values represent the means ± the SD of data derived from at least three independent experiments performed in quadruplicate.

<sup>c</sup>SI, Selectivity Index (determined as CC<sub>50</sub>/EC<sub>50</sub>).

**Table 3.** Comparison of the activity of BBR against AD169 and drug-resistant HCMV strains.

HCMV Strain	Drug resistance	BBR EC <sub>50</sub> <sup>a</sup> (μM)	Control <sup>b</sup> EC <sub>50</sub> (μM)
AD169	None	2.35 ± 0.35	N.D.
GDG <sup>r</sup> P53	GCV, CDV	1.45 ± 0.08	75 ± 5
PFA <sup>r</sup> D100	FOS, ACV	1.40 ± 0.57	305 ± 18

<sup>a</sup>50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs in HFF cells. Reported values represent the means ± the SD of data derived from at least three independent experiments in triplicate.

<sup>b</sup>GCV was used for GDG<sup>r</sup>P53 and FOS for PFA<sup>r</sup>D100.

N.D., not determined.


**Table 4.** Antiviral activity of BBR against MCMV.


Compound	EC <sub>50</sub> <sup>a</sup> (μM)	CC <sub>50</sub> <sup>b</sup> (μM)	SI <sup>c</sup>
BBR	1.95 ± 0.35	192 ± 12	98
CDV	0.53 ± 0.18	> 250	>472


<sup>a</sup>50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs against MCMV Smith in NIH 3T3 cells. Reported values represent the means ± the SD of data derived from three independent experiments in triplicate.

<sup>b</sup>50% Cytotoxic Concentration, the compound concentration that results in 50% of cytotoxicity, as determined by MTT assays in NIH 3T3 cells. Reported values represent the means ± the SD of data derived from at least three independent experiments performed in quadruplicate.




<sup>c</sup>SI, Selectivity Index (determined as CC<sub>50</sub>/EC<sub>50</sub>).













**A****B****C**